ClinicalTrials.gg
RecruitingNCT05373498PRO-CHDUpdated Jan 16, 2025

Resuscitation Registry in CHD

An observational study in Cardiac Arrest and Congenital Heart Disease, sponsored by Leipzig Heart Science gGmbH. Recruiting at 3 sites in Germany. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Leipzig Heart Science gGmbH · Observational

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
400
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Heart Arrest with a site in Germany — 8 open to participants now, 10 under way, none of them phase 3. Heart Arrest · Germany.

Planned enrollment
6th of 15
400 · median 200
Started
2022
with 2 others
Observational
15 of 38
4 open now
Registered
28th of 38
by date

Among the 38 studies in Heart Arrest with a site in Germany, this one is the 6th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2022, is one of 15 observational ones, and was the 28th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

8 of the 38 studies in Heart Arrest with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Heart Arrest with a site in Germany, or all of them as a file.
02

Study summary

Children with congenital heart defects are far more likely to suffer a cardiovascular arrest and be in the need of cardiopulmonary resuscitation than healthy children or those with diseases of other organ systems, especially after cardiothoracic surgery. Due to a lack of data, the exact number of resuscitations in this patient cohort, as well as the morbidity and mortality, is unknown. This study aims to register all cardiovascular arrests in pediatric patients with congenital heart disease and study the mortality and morbidity with a special focus on the neurodevelopmental outcome.

Read the detailed description

Background and aim: Children with heart defects, especially those after heart surgery, have an up to ten times higher risk for an in-hospital cardiac arrest, compared to children without heart disease. Although this patient cohort is particularly vulnerable, these events and outcomes are not systematically monitored in Germany. We designed a prospective multicenter-registry study aiming to record in-hospital cardiac arrests of children with congenital- (CHD) and acquired heart disease in Germany.

Methods: A web-based registry was designed, prospectively collecting data (patient´s demographics, CPR data, post-resuscitation care and clinical course, neurological outcome and follow-up), according to the Utstein template. All children (0-18 years) with heart disease suffering a cardiac arrest requiring resuscitation of ≥ two minutes will be included. The primary outcome is survival to discharge, the secondary outcome is morbidity, with a particular focus on neurological morbidity. An inclusion of 10-20 children/centre/year is anticipated. As this is an observational study, no intervention is planned.

Results: This registry will provide data on the mortality, early and mid-term neurologic outcome, and quality of life after cardiac arrest of children with heart disease in Germany. Correlations between patients´ characteristics, resuscitation characteristics and post-resuscitation care with primary and secondary outcomes will be analyzed.

Conclusions: By systematically recording and analyzing the outcome after in-hospital cardiac arrest in children with CHD, this study is an important first step to close knowledge gaps regarding the risk factors and outcome of cardiac arrest in this patient group, and aims to improve care and outcomes of these vulnerable patients.

03

Conditions studied

  • Cardiac Arrest
  • Congenital Heart Disease

Keywords

  • pediatric resuscitation outcome
  • congenital heart disease
  • neurodevelopmental outcome
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children: 0 - 18 years

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • congenital heart defects, congenital heart arrhythmia, familial cardiomyopathies, inflammatory heart diseases
  • pediatric resuscitation (chest compressions ≥2min) in hospital or on arrival in hospital
  • age \<18 years
  • of the parents or legal representative

Exclusion criteria

Exclusion Criteria:

  • absence or withdrawal of of the parents or legal representative
  • do-not-resuscitate-order (DNR)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. survival to hospital discharge

    Time frame: until the date of discharge or death from any cause, whichever came first, assessed up to 2 months

Secondary outcomes

  1. Number of return of spontaneous circulation

    Time frame: until the date of discharge or spontaneous circulation from any cause, whichever came first, assessed up to 2 months

  2. Rate of morbidity

    Time frame: until 2 years

07

Study locations

1 of 3 sites recruiting
  • Herzzentrum Leipzig
    Leipzig, Sachsen 04289, Germany
    Recruiting
    • Franziska Markel, Dr. med. · Contact
    • Michael Weidenbach, PD Dr. med. · Contact
  • Deutsches Herzzentrum Berlin
    Berlin, 13353, Germany
    Not yet recruiting
    • Katharina Schmitt, Prof. Dr. med. · Contact
    • Peter Kramer, Dr. med. · Contact
  • Universitätsklinikum Bonn (AöR)
    Bonn, 53127, Germany
    Not yet recruiting
    • Valérie Amann, Dr. · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2030, 100 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 100 months is above that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
May 13, 2022
StartActual
Aug 18, 2022
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2032
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05373498
Lead sponsor
Leipzig Heart Science gGmbH
Collaborators
Heart Center Leipzig - University Hospital, Zentrum für Klinische Studien Leipzig, Deutsche Gesellschaft für Pädiatrische Kardiologie und Angeborene Herzfehler e.V., Stiftung KinderHerz
Responsible party
Sponsor
First posted
May 13, 2022
Start date
Aug 18, 2022
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Jan 16, 2025

Study contacts

Franziska Markel, Dr. med.
Contact
Franziska.Markel@helios-gesundheit.de
+49341865253025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion